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 14 
Abstract  15 
Hair-follicle-derived stem cells (HSCs) originating from the bulge region of the mouse vibrissa hair 16 
follicle are able to differentiate into neuronal and glial lineage cells. The Tropomyosin receptor 17 
kinase A (TrkA) receptor that is expressed on these cells plays key roles in mediating the survival 18 
and differentiation of neural progenitors as well as in the regulation of the growth and regeneration 19 
of different neural systems. In this study, we introduce the OptoTrkA system, which is able to 20 
stimulate TrkA activity via blue-light illumination in HSCs. This allows us to determine whether 21 
TrkA signaling is capable of influencing the proliferation, migration and neural differentiation of 22 
these somatic stem cells. We found that OptoTrkA was able to activate downstream molecules such 23 
as ERK and AKT with blue-light illumination, and subsequently able to terminate this kinase 24 
activity in dark. HSCs with OptoTrkA activity showed an increased ability for proliferation and 25 
migration and also exhibited accelerated neuronal and glial cell differentiation. These findings 26 
suggest that the precise control of TrkA activity using optogenetic tools is a viable strategy for the 27 
regeneration of neurons from HSCs, and also provides a novel insight into the clinical application 28 
of optogenetic tools in cell-transplantation therapy.  29 
 30 
1. Introduction 31 
Different types of stem cells are being widely investigated in cell-transplantation and regenerative 32 
therapies for neural defects caused by congenital and acquired pathologies[1-4]. However, the route 33 
to the clinic for such cell-based therapies is a long one due to prevalent issues such as alloimmune 34 
rejection, the availability of cell sources and the potential long-term risk for tumorigenesis[4-6]. Hair 35 
follicles are an easily accessible structure on the skin and the stem cells harbored within them can 36 
consistently undergo self-renewal.[7,8] Hair-follicle-derived stem cells (HSCs) isolated from the 37 
bulge region of hair follicles were able to differentiate into neuronal and glial cells in vitro and also 38 
regenerate neurons in animal recipients[8-10]. HSCs are an ideal cell source for neural regeneration 39 
not only due to its differentiation potency to neural cell types, but also its reduced tumorigenicity 40 
as somatic stem cells, easy accessibility, as well as its lower rate for immunologic rejection during 41 
autologous transplantation.  42 
Neurotrophin signaling is a key process that determines neural stem cell function, influencing 43 
cell survival, cell division and differentiation. These effects carry on to modulate functions in fate-44 
determined cells, such as axonal and dendritic growth of neurons, cell death, neurotransmitter 45 
secretion and neuronal activity[11]. Neurotophin signaling is traditionally mediated through ligand 46 
binding to the Trk receptor tyrosine kinase family and, with less affinity, to the p75 neurotrophin 47 
receptor[11-13]. Although Trk receptors have been investigated in a variety of different cell types, 48 
little is known about its function in HSCs during neural differentiation. As key Trk-mediated effects 49 
such as active proliferation, cellular migration and differentiation are critical processes in cell graft 50 
survival and its ability to fully regenerate neurons after transplantation, various groups have 51 
examined the effect of Trk receptors activation in a variety of neural progenitors by using techniques 52 
such as genetic overexpression or by agonist-induced activation of the receptor[13-15]. However, 53 
these approaches are not feasible for clinical applications. One major issue is that certain receptors 54 
such as TrkC can act as an oncogene in a variety of tumor cells, and manipulation of TrkC over-55 
expression using genetic methods has been acknowledged to result in an extremely high 56 
tumorigenic potential. Furthermore, manipulation of exogenous Trk activity using such methods 57 
results in receptor levels persisting in a non-physiological manner even after neuronal 58 
differentiation. Also, using small-molecule agonists of Trk receptors has its own caveats; a plethora 59 
of unknown off-target effects suggests that rigorous testing before clinical use will be required[16,17]. 60 
Therefore, strategies that can enact precise control on the activities of Trk receptors in HSCs such 61 
as through some form of “biochemical switch” need to be developed in order to manipulate neural 62 
regeneration efficiency in these cells, with the condition that such a switch must be able to terminate 63 
Trk activity after regeneration processes to ensure that levels of Trk receptors can be restored to 64 
physiological levels after fate-determination.      65 
 Emerging cutting-edge optogenetic techniques allow for spatiotemporal regulation of the 66 
activity of single molecules[18-21]. Previously, we developed an optogenetic tool (OptoTrkA) that 67 
allows reversible activation of TrkA signaling by the fusion of the intracellular domain of TrkA 68 
(TrkA-ICD) with the light-oxygen-voltage domain of aureochrome 1 from Vaucheria frigida 69 
(AuLOV)[18]. We expect that OptoTrkA is only activated after excitation by light and this activation 70 
is spontaneously resolved in the dark and activation of TrkA using the OptoTrkA system will 71 
influence the proliferation, migration and neural differentiation (to neuronal and glial cell types) of 72 
HSCs.  73 
In this study, we used the OptoTrkA system within primary cultured HSCs isolated from mouse 74 
vibrissa hair follicles and found that light induced TrkA activity was able to promote cell 75 
proliferation, migration and differentiation into neuronal and glial cells in vitro. The results of our 76 
study demonstrated the optogenetically-controlled TrkA activity in HSCs and revealed the 77 
functional role of TrkA in driving the neurogenesis of HSCs. 78 
 79 
2. Results 80 
2.1. Optogenetic Activation of TrkA in HSCs 81 
Previously, we developed an optogenetic system (OptoTrkA) that allows for TrkA activation upon 82 
controlled light excitation (Figure 1A and 1B). This system was constructed by fusing the 83 
intracellular domain of TrkA (TrkA-ICD) with the light-oxygen-voltage domain of from Vaucheria 84 
frigida aureochrome 1 (AuLOV). Upon light excitation, the homo-association of AuLOV pulls two 85 
copies of TrkA-ICD within close proximity and further initiating its cross- and autophosphorylation 86 
(Figure 1B). HSCs originated from bulge region of mouse vibrissa hair follicle were primary 87 
cultured in vitro and transfected with the plasmid expressing OptoTrkA (Figure 1C). HSCs with 88 
OptoTrkA transfection were subjected to cellular analyses, including BrdU staining, wound-healing 89 
assay, directed differentiation analysis, etc. in order to determine the functional effects of TrkA on 90 
the proliferation, migration and neural differentiation of HSCs (figure 1D).  91 
 92 
2.2. Isolation and Characterization of HSCs 93 
Mouse vibrissa hair follicle explants were isolated according to the procedure as described in the 94 
Methods (Figure 2A, i-iv). After the culture of mouse follicle explants, we found that proliferative 95 
cells migrate outward from the explant in migration medium after 2-3 days, whereupon the explant 96 
was removed on Day 4 (Figure 2B). In general, we found that cell numbers ranged from between 97 
8,000 to 10,000 per explant when cultured in expansion medium on Day 7 whereupon these cells 98 
were enzymatically dissociated for passaging (Figure 2B). Characterization of primary cultured 99 
cells was performed by immunofluorescence staining of markers such as Nestin, p75, Sox10 and 100 
Oct4. We found that early migrated cells (Day 3) expressed markers such as Nestin, p75 and Sox10 101 
(Figure 2C). After passaging, sub-cultured cells were found to also be Nestin and Oct4 double 102 
immunoreactive (Figure 2D). In addition, we isolated mRNA from these cells and were able to 103 
detect the expression of stem cell markers such as Oct4, Sox2 and Nanog by reverse-transcription 104 
PCR (Figure 2E). Meanwhile, we also found that expression of neural stem cell markers, including 105 
Nes (encoding Nestin) Sox9, Sox10 and Ngfr (encoding p75NTR), were also found to be expressed 106 
in these cells (Figure 2E). In summary, the cells isolated from mouse vibrissa hair follicle exhibited 107 
markers of stem cells, especially neural stem cells, which were similar to the hair-follicle-derived 108 
stem cells (HSCs) reported previously [7,9,10]; thus, we also termed these cells as HSCs in our present 109 
study.  110 
 111 
2.3. Light-stimulated OptoTrkA Activity Enhances the Proliferation and Migration of HSCs 112 
Previous studies have reported that TrkA selectively promotes cell proliferation and migration or 113 
may even result in cell death pathway activation in a variety of cell types[16,22-24]. To determine 114 
whether blue light-induced OptoTrkA activity has any effect on the proliferation and migration of 115 
HSCs, we introduced OptoTrkA into primary cultured HSCs. This was followed by BrdU staining 116 
to examine proliferation and a wound healing assay to examine cellular migration. HSCs with light-117 
induced activation of OptoTrkA (pOptoTrkA-light) showed a significantly higher percentage of 118 
BrdU immunoreactivity as compared with those HSCs in pEGFP-dark, pOptoTrkA and 119 
pOptoTrkA-dark groups, which suggests that activation of OptoTrkA was able to increase the 120 
proliferation of HSCs (Figure 3A and 3B). In the wound healing assay, HSCs with blue light-121 
activated OptoTrkA showed a significantly higher ability to migrate into the wound over a period 122 
of 12h and 24h when compared to the other three control groups (Figure 3C and 3D). By counting 123 
the average distance between each cell to its closest neighbor at the 24h time point, we found that 124 
HSCs were more dispersed in the light-activated OptoTrkA group as compared to the cells in other 125 
groups (Figure 3E). We also performed the TUNEL assay and Caspase-3 staining of HSCs with and 126 
without OptoTrkA activity and found no significant difference in cell apoptosis or cell death 127 
(supplementary figures). These gain-of-function studies of OptoTrkA therefore suggest that the 128 
proliferation and migration of HSCs could be enhanced by the light-induced activation of OptoTrkA 129 
in vitro. 130 
 131 
2.4. Light-induced Activation of OptoTrkA can Boost Neuronal Cell Differentiation of HSC 132 
To determine whether activated OptoTrkA can improve HSC neuronal cell differentiation, we 133 
performed a directed differentiation protocol followed by immunofluorescence staining of neuronal 134 
markers. pOptoTrkA was transfected into primary cultured HSCs, and these HSCs were induced 135 
into neurons in neuronal cell differentiation medium. By examining neuronal markers Tuj1, PGP9.5 136 
and Map2, we found that all the HSCs in four different groups were able to differentiate into neurons 137 
(Figure 4A, 4D and Supplementary Figure 1A). However, the activated OptoTrkA group had a 138 
significantly higher percentage of Tuj1 and PGP9.5 immunoreactive cells as compared to those in 139 
the control groups (Figure 4B and 4E). To further confirm that activation of OptoTrkA can promote 140 
neuronal cell differentiation, we analyzed the number of neuronal cells, which showed a fibrous 141 
cell structure. We found that the HSCs with activated OptoTrkA were able to show a higher 142 
percentage of cells with fibrous morphology as compared to the controls (Figure 4C and 4F). These 143 
findings reveal that OptoTrkA not only promotes the neuronal differentiation of HSCs but also can 144 
accelerate the maturation of neuronal cells.  145 
 146 
2.5. Light-induced Activation of OptoTrkA can Enhance Glial Cell Differentiation of HSCs 147 
Next, we sought to further understand if the light-induced activation of OptoTrkA could also 148 
promote glial cell differentiation of HSCs. A similar protocol to our neuronal cell differentiation 149 
protocol was used, but differentiation was induced by using a glial cell induction medium. In these 150 
experiments, we found that HSCs with activated OptoTrkA showed a significantly higher 151 
percentage of glial differentiation as determined by immunofluorescence staining of Fabp7 (Figure 152 
5A and 5B) and S100b (Figure 5D and 5E), but not of GFAP (an astrocyte marker, Supplementary 153 
figure 1C and 1D). In addition, higher fluorescence intensity of Fabp7, S100b and GFAP was 154 
detected in the HSCs with activated OptoTrkA as compared with those in the control groups (Figure 155 
5C, 5F and Supplementary figure 1E). In conclusion, light-activated OptoTrkA was able to enhance 156 
the glial cell differentiation of primary cultured HSCs. 157 
 158 
2.6. OptoTrkA can be Stimulated by Blue-light Exposure and Spontaneous Deactivated in the 159 
Dark 160 
To interrogate whether OptoTrkA is only activated by blue-light exposure, we performed Western 161 
blotting to examine the phosphorylation of downstream signaling pathways regulated by TrkA, 162 
including ERK and AKT protein. We transfected the OptoTrkA protein expression plasmid 163 
(pOptoTrkA) into HEK293T cells in vitro and stimulated OptoTrkA activity by using blue-light 164 
illumination cycles for 12 hours (0.2 mW/cm2) (Figure 6A). Along the treatment group 165 
(pOtpoTrkA-light), three control groups were set up: cells infected with pEGFP-N1 vector and 166 
maintained in the dark (pEGFP-dark); cells infected with pOptoTrkA plasmid and maintained in 167 
the dark (pOptoTrkA-dark), and cells infected with pEGFP-N1 and illuminated with blue light 168 
(pEGFP-light). Western blotting showed that blue light stimulated optogenetic TrkA led to 169 
increased phosphorylation of ERK1/2 (p-Thr202/Try204) and AKT (p-Ser473) in HEK293T cells, 170 
however, illumination of EGFP only controls or OptoTrkA without illumination did not have a 171 
significant effect on activating ERK and AKT signaling pathways (Figure 6B, 6C and 6D). 172 
 Thereafter, the four experimental groups were all equally placed into the dark for another 24 173 
hours to spontaneously deactivate OptoTrkA stimulation. Phosphorylation of ERK1/2 and AKT was 174 
determined again by Western blotting. No significant differences in p-ERK1/2 and p-AKT could be 175 
detected in the OptoTrkA-light cells when compared to that in the other three control groups which 176 
did not have both pOptoTrkA and prior illumination (Figure 6E, 6F and 6G). Taken together, this 177 
data suggests that OptoTrkA can be stimulated to activate downstream ERK and AKT signal 178 
pathways using blue-light illumination, and this can be spontaneously converted back to an 179 
inactivated state when placed into the dark. 180 
 181 
3. Discussion 182 
 183 
The overall goal of this study is to determine whether stimulation of TrkA activity controlled by 184 
blue light illumination is able to improve cell proliferation, differentiation and neural differentiation 185 
of HSCs. Towards this goal, we developed an optogenetic tool to stimulate TrkA activity in HSCs 186 
and deciphered the function of TrkA in these somatic stem cells. We found that light-induced 187 
activation of OptoTrkA was able to promote the proliferation of HSCs, which suggests that 188 
manipulation of TrkA activation in HSCs has the potential to improve cell survival and increase the 189 
population size of cell grafts after transplantation. Second, HSCs with OptoTrkA activity also 190 
showed enhanced migratory ability, which has the effect of improving cell grafts colonization in 191 
transplant recipient tissue where there is a need to regenerate neurons in large areas or across long 192 
distances. Third, HSCs with activated OptoTrkA demonstrated a significantly accelerated neural 193 
differentiation towards neuronal and glial lineages. These results suggest that stimulating TrkA 194 
activity using optogenetic tools in HSCs is a viable therapeutic strategy to regenerate neural defects 195 
in future clinical applications. 196 
TrkA, together with TrkB, TrkC and p75NTR, participate in mediating neurotrophin (NT) 197 
signaling. Of the traditional neurotrophic factors, NGF binds TrkA, BDNF and NT-4/5 binds to 198 
TrkB, NT-3 binds to TrkC, though all neurotrophic factors are also able to bind to low-affinity 199 
neurotrophin receptor p75NTR[11,25,26]. The downstream pathways from Trk receptors share many 200 
common protein substrates such as the Ras/Mapk/Erk, PLCγ, and PI3K/AKT signaling 201 
pathways[24,25]. To our present knowledge, ERK1/2 plays a key role in neuronal survival and axonal 202 
maintenance after neural damage[27,28], and the AKT signaling pathway controls cytoskeletal 203 
dynamics for axon elongation and cell migration during neural regeneration[14,29,30]. We found that 204 
OptoTrkA is able to significantly activate both ERK1/2 and AKT pathways, which we determined 205 
using phosphorylation of ERK1/2 (p-Thr202/Try204) and AKT (p-Ser473) in our western blotting 206 
assay (Figure 3). Previous studies by our group and others have shown that two tyrosine residues, 207 
Y490 and Y785, which are located within the intracellular domain of TrkA, serve as the primary 208 
phosphorylated sites for triggering downstream ERK1/2, AKT and PLCγ activation during neuronal 209 
differentiation in PC12 cells[18,31,32]. However, even though the functional mechanism of TrkA in 210 
HSCs still remains unclear, similar molecular interactions in PC12 may also exist in HSCs. 211 
Therefore, specific phosphorylation inhibitors such as U0126 which targets ERK1/2 and LY294002 212 
which targets AKT may help to interrogate the detailed protein-protein interactions during TrkA 213 
activation in HSCs and can be used for further studies. 214 
Multipotent stem cells isolated from hair and skin have been successfully used for cell-215 
transplantation therapy in spinal cord-injured and neonatal shivered mice[33-35]. High throughput 216 
profiling by RNA sequencing showed that the neural progenitors from both rodent and human hair 217 
follicles have gene expression signatures similar to those of the mouse neural crest stem cells and 218 
human neuronal cells[36,37]. HSCs, therefore, are a good target for further studies into genetic 219 
modifications and clinical applications in regenerative medicine towards repairing neural defects. 220 
Enlightened by the previous findings that show that Trk receptor activation can significantly 221 
increase the survival rate and neural regeneration efficiency in stromal cell transplantation[13-15,23], 222 
we activated TrkA in HSCs and determined that modulating TrkA activity has beneficial roles in 223 
improving proliferation, migration and neural differentiation. As Trk signaling has previously been 224 
identified in various solid tumors[16,17], we used a cautious approach to stimulate TrkA activity via 225 
optogenetic tools which are only active during light illumination to effectively reduced the long-226 
term tumorigenic risk. Moving this approach to the clinic is aided by the fact that novel nanometer 227 
materials to facilitate deep-tissue light delivery have seen significant improvement in the last 228 
decade[38-40]. Therefore, in vivo investigation of TrkA activation in HSCs by optogenetic control for 229 
regenerating neurons is a viable next step in improving neural regeneration after transplantation.   230 
 231 
4. Conclusion 232 
In conclusion, we have provided evidence that shows that TrkA activation promotes cell 233 
proliferation, migration and neural differentiation of stem cells isolated from the bulge region of 234 
mouse vibrissa hair follicle. In addition, with optogenetic tools, TrkA signaling activity can be 235 
precisely controlled by blue light illumination. It is hoped that our work will bring a novel angle to 236 
cell-transplantation therapy using somatic stem cells for neural regeneration. 237 
 238 
5. Experimental Section 239 
Animals: Wild-type C57BL/6J mice were purchased from the Jackson Laboratory. All mice 240 
were maintained on an artificial 12/12 hours light/dark cycle. Ethical approval for all animal 241 
procedures was obtained from the Sun Yat-Sen University Institutional Animal Care and Use 242 
Committee (Approval No. SYSU-IACUC-2020-B0538).  243 
Cell culture: The adult mice (6-8 weeks) were sacrificed by cervical dislocation. The mouse 244 
head was sterilized for 1-2 min in a solution consisting of a 50% hydrogen peroxide and a 5% 245 
povidone-iodine solution. The whisker pads were dissected and immersed in 1× Dulbecco’s 246 
phosphate-buffered saline (DPBS). The vibrissa hair follicles from the whisker pads were then 247 
further dissected by removing the hair dermis, the papilla sebaceous gland and the connective tissue 248 
capsule. A single explant containing HSCs was cultured in 𝛼𝛼 -MEM medium (Gibco, 32571) 249 
containing 10% fetal bovine serum (FBS) (Gibco, 16000044). Coverslips for explant culture were 250 
coated with 20 μg/ml collagen type I (BD,354236). After 3 days in culture, the hair follicle explants 251 
were removed and emigrated HSCs were further cultured in cell expansion medium which contains 252 
DMEM/F12 (Gibco, 1133032), 10% FBS, 1x B27 supplement, 10 ng/ml fibroblast growth factor 253 
(FGF) (Gibco, PHG0266-25), epidermal growth factor (EGF) (Gibco PHG0311), glial cell-derived 254 
neurotrophic factor (GDNF) (R&D System, 212-GD). Primary-cultured HSCs were dissociated and 255 
passaged using Accutase (Millipore, SCR005) on Day 7. 256 
Differentiation tests: To induce the differentiation of HSCs into neuronal cells, the cells were 257 
transferred to a modified neuronal differentiation medium containing DMEM/F12, 1×B27 258 
supplement (Gibco, 17504-044), 1×N2 supplement (Gibco,17502-048), 20 ng/ml BMP2 (Gibco, 259 
PHC7145), and 1 μM all-trans-retinoic acid (Sigma, R2625) for 3 days. To induce differentiation 260 
of HSCs into glial cells, the cells were transferred to a modified glial differentiation medium 261 
containing DMEM/F12, 2 mM L-glutamine (Gibco, 25030081), 2 ng/ml insulin (Sigma, I1882), 262 
1×B27 supplement (Gibco, 17504-044), 1×N2 supplement (Gibco, 17502-048), and 50 ng/ml 263 
BMP2 (Gibco, PHC7145) for 3 days.  264 
Plasmid construction and transfection: The OptoTrkA plasmid was constructed as previously 265 
described[18]. Cells were transfected using Lipofectamine Stem Transfection Reagent (Invitrogen, 266 
STEM00008) following the manufacturer’s instructions. Successful transfection was confirmed by 267 
fluorescence microscopy 24 h post-transfection. 268 
Light stimulation: The instrument used for blue light illumination was described previously[18]. 269 
To stimulate TrkA activity using blue light in HSCs, a 12-well plate containing OptoTrkA-270 
transfected cells was illuminated on a 10/50 minutes on/off cycle. The light intensity was adjusted 271 
to 0.2 mW/cm2 at the position of the cells.  272 
Immunofluorescent staining and western blotting: Cells grown on collagen type I-coated 273 
coverslips were fixed with 4% paraformaldehyde for 15min at room temperature followed by 3 274 
rounds of PBS rinsing at 10 min each, The cells were then blocked using 1% BSA (Sigma, 9418) 275 
in PBS containing 1% Triton X-100 (USB, 22686) for 1h. Primary antibodies (Table 1) were diluted 276 
at the manufacturer’s recommended dilution ratio in blocking buffer and incubated with the cells at 277 
4℃ overnight. Secondary antibodies were diluted at a ratio of 1:300 in blocking buffer for 1h at 278 
room temperature. After washing 3 times in PBS containing 0.5% Tween-20 (USB, 20605), cells 279 
were counter-stained with 0.15% (w/v) DAPI (Sigma, 9542) in PBS and mounted using FluorSave 280 
Reagent (Millipore, 345789). Fluorescent images were photographed using an epifluorescence 281 
microscope (Olympus). For BrdU assays, BrdU reagent was added into culture medium 2h prior to 282 
fixation, after which genomic DNA was denatured using 2N HCl for 30 min at room temperature 283 
to expose BrdU-labelled DNA before following standard immunostaining protocols. For Western 284 
Blotting, cells were lysed in RIPA buffer (CST, 9806) containing PMSF (Sigma, 10837091001) and 285 
cOmplete™ Protease Inhibitor Cocktail (Roche, 11697498001) on ice for 10 min, followed by 286 
centrifugation at 12,000g for 10 min to remove the insoluble fraction. Protein concentration was 287 
measured using the BCA kit (Pierce, 23227). Protein samples were then equalized by dilution in 288 
SDS sample buffer and then boiled at 99℃ for 5 min before SDS-PAGE. Samples on the acrylamide 289 
gel were transferred to activated PVDF membranes (Bio-Rad, 162-0184) and immunoblotted using 290 
primary antibodies diluted in 5% BSA:TBST at a ratio of 1:1000, followed by appropriate HRP-291 
conjugated secondary antibodies (diluted at 1:10,000), and finally developed by using the Clarity 292 
Western ECL substrate (Bio-Rad, 170-5060). 293 
Wound healing and cell dispersion assay: A cell-free area for wound healing assay was created 294 
by physical exclusion using a commercialized culture insert (ibidi, 81176) following the 295 
manufacturer’s protocol. To avoid interference from cell proliferation, cells were starved in serum-296 
free DMEM/F12 medium. Images of all groups were taken at 12h, 24h and 36h. At the 12h 297 
timepoint, cells that migrated into the cell-free area in each group were selected for the cell 298 
dispersion assay by measuring the distance of each cell to its closest neighbor.  299 
Statistical Analysis: The ImageJ software was used for image analysis, including the 300 
quantification of cell distance, cell number and fluorescence intensity. All quantitative results were 301 
displayed as the mean ± S.D. Statistical significance was assessed using non-parametric ANOVA 302 
(Kruskal-Wallis with Dunn’s multiple comparisons post-test) using Prism 7 (GraphPad). Statistical 303 
significance was set at p<0.05 with a 95% confidence interval. 304 
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Figure legends 382 
 383 
Figure 1. Schematic illustration of activation of OptoTrkA in HSCs. A) OptoTrkA-transfected 384 
HSCs and control HSCs were cultured in a 12-well plate which was placed on the LED light box. 385 
Light illumination was set to a 10-min-on, 50-min-off cycle. B) HSCs were isolated from the bulge 386 
region of mouse vibrissa hair follicles. C) Upon blue light illumination, the photosensitive protein, 387 
AuLOV dimerizes TrkA-ICD, which leads to activation of TrkA signaling as detected by 388 
autophosphorylation. D) The function of OptoTrkA in regulating the proliferation, migration and 389 
neural differentiation of HSCs was investigated in this study.  390 
 391 
Figure 2. Primary culture of HSCs from hair follicle explant. A) The whisker pads of the adult 392 
mouse were dissected (i) and placed in PBS under a stereoscopic microscope (ii). Single hair 393 
follicles are then isolated (iii). A single bulge explant for culture was obtained by removing the 394 
connective tissue capsule (iv). B) The explant isolated from the mouse vibrissa hair follicles of 395 
postnatal mice is cultured on collagen type-I coated coverslips. The HSCs migrate from hair follicle 396 
explant on approximately Day 2 and the explant was removed on Day 4. Hereafter, the HSCs 397 
population was expanded for a subsequent 3 days before passaging. Scale bar: 200 μm. C) After the 398 
bulge explants were removed, the cells were stained for the expression of Nestin, Sox10 and p75NTR. 399 
Scale bar: 20 μm. D) After sub-culturing, HSCs were found to be Nestin and Oct4 double 400 
immunoreactive. Scale bar: 100 μm. E) The expression of Oct4, Sox2, Nanog, Nes, Sox9, Sox10 401 
and Ngfr was determined by reverse-transcription PCR. 402 
 403 
Figure 3. Light-induced activation of OptoTrkA promotes proliferation and migration of 404 
HSCs. A) Immunofluorescence staining of BrdU in OptoTrkA-transfected HNCSs and sham-405 
transfected HNCSs with or without continuous 12h cyclic blue light illumination. Scale bar: 100 406 
μm. B) Bar chart showing the average percentage of BrdU-positive HSCs. Kruskal–Wallis test 407 
followed with multiple comparisons by Dunn's test, *P<0.05, n=4. C) Wound healing assays 408 
demonstrating that the gap area covered by migrating HSCs with light-activated TrkA (OptoTrkA-409 
light) is larger than other control groups at 12h and 24h. Scale bar: 100 μm. D) Line graph showing 410 
the percentage of the gap area covered by migrating HSCs during the wound healing assay. 411 
Kruskal–Wallis test followed with multiple comparisons by Dunn's test, *P<0.01, **P<0.01, n=10. 412 
E) Bar chart showing that the average distance of each cell to its nearest neighbor in the OptoTrkA-413 
light group is longer as compared to the cells in other control groups. Kruskal–Wallis test followed 414 
with multiple comparisons by Dunn's test, **P<0.01, n=10. 415 
 416 
Figure 4. Light-induced activity of OptoTrkA promotes neuronal cell differentiation of HSCs. 417 
A) Photomicrographs showing Tuj1 immunofluorescence staining of the neuronal differentiated 418 
HSCs with and without OptoTrkA activity. Scale bar: 100 μm. B) A bar chart showing the 419 
percentage of Tuj1 immunoreactive cells. Kruskal–Wallis test followed with multiple comparisons 420 
by Dunn's test, **P<0.01, n=4. C) Bar chart showing the percentage of the cells with fibrous 421 
morphology among Tuj1 immunoreactive cells. Kruskal–Wallis test followed with multiple 422 
comparisons by Dunn's test, **P<0.01, n=4. D) Photomicrographs showing PGP9.5 423 
immunofluorescence staining of neuronal-differentiated HSCs with and without OptoTrkA activity. 424 
Scale bar: 100 μm. E) Bar chart showing the percentage of PGP9.5 immunoreactive cells. Kruskal–425 
Wallis test followed with multiple comparisons by Dunn's test, *P<0.01, n=4. F) Bar chart showing 426 
the percentage of the cells with fibrous morphology among PGP9.5 immunoreactive cells (n=4). 427 
Kruskal–Wallis test followed with multiple comparisons by Dunn's test, **P<0.01, n=4. The 428 
relative quantifications are normalized to the leftmost group (as control) and compared between 429 
each group for significance analysis.  430 
 431 
Figure 5. Light-induced activity of OptoTrkA promotes glial cell differentiation of HSCs.  432 
A) Photomicrographs showing Fabp7 immunofluorescence staining of glial-differentiated HSCs 433 
with and without OptoTrkA activity. Scale bar: 100 μm. B) Bar chart showing the percentage of 434 
Fabp7 immunoreactive cells. Kruskal–Wallis test followed with multiple comparisons by Dunn's 435 
test, *P<0.01, n=4. C) Bar chart showing the relative immunofluorescence intensity of Fabp7 436 
normalized to DAPI. Kruskal–Wallis test followed with multiple comparisons by Dunn's test, 437 
***P<0.01, n=4. D) Photomicrographs showing S100b immunofluorescence staining of glial 438 
differentiated HSCs with and without OptoTrkA activity. Scale bar: 100 μm. E) Bar chart showing 439 
the percentage of S100b immunoreactive cells. Kruskal–Wallis test followed with multiple 440 
comparisons by Dunn's test, **P<0.01, n=4. F) Bar chart showing the relative immunofluorescence 441 
intensity of S100b normalized to DAPI. Kruskal–Wallis test followed with multiple comparisons 442 
by Dunn's test, *P<0.01, n=4. The relative quantifications are normalized to the leftmost group (as 443 
control) and compared between each group for significance analysis.  444 
 445 
Figure 6. Light-induced OptoTrkA activation increased the phosphorylation of ERK1/2 and 446 
AKT. A) OptoTrkA-transfected HEK293T cells and control cells were cultured in a 12-well plate 447 
which was placed on an LED light box. Light illumination was set to a 10-min-on, 50-min-off cycle. 448 
B) Western blotting showed that cells with OptoTrkA transfection display increased 449 
phosphorylation of ERK1/2 and AKT activation when exposed to blue light for 12 hours. C) and D) 450 
Bar charts demonstrate quantifications of relative intensities of the western blotting in (B). Kruskal–451 
Wallis test followed with multiple comparisons by Dunn's test, *p<0.01, n=3. E) Western blotting 452 
showed that cells with OptoTrkA transfections display no significant difference compared to 453 
controls when continuously illuminated with cyclic blue light for 12 hours and placed in the dark 454 
for another 24 hours. F) and G) Bar charts demonstrate quantifications of relative intensities of the 455 
western blotting in (E). Kruskal–Wallis test, P>0.05, n=3. Quantifications of Western blots are first 456 
normalized to the extreme left group (controls) and compared to each group for significance 457 
analysis.  458 
 459 
 460 
Supplementary figure 1. Immunofluorescent staining of Map2 and GFAP. A) 461 
Photomicrographs showing Map2 immunofluorescence staining of the neuronal differentiated 462 
HSCs with or without OptoTrkA activity. Scale bar: 50 μm. B) A bar chart showing the percentage 463 
of Map2 immunoreactive cells. Kruskal–Wallis test, P>0.05, n=4. C) Photomicrographs showing 464 
GFAP immunofluorescent staining of glial-differentiated HSCs with or without OptoTrkA activity. 465 
Scale bar: 50 μm. D) Bar chart showing the percentage of GFAP immunoreactive cells. Kruskal–466 
Wallis test, P>0.05, n=4. E) Bar chart showing the relative immunofluorescence intensity of GFAP 467 
normalized to DAPI. Kruskal–Wallis test followed with multiple comparisons by Dunn's test, 468 
*P<0.01, n=4. The relative quantifications are normalized to the leftmost group (as control) and 469 
compared between each group for significance analysis. 470 
 471 
Supplementary figure 2. Activation of OptoTrkA did not induce apoptosis or cell death. A) 472 
TUNEL staining of OptoTrkA activated HSCs and control HSCs. Arrows indicated the TUNEL 473 
positive cells. Scale bar: 100 μm. B) Immunofluorescence staining of Caspase-3 (Casp3) of 474 
OptoTrkA activated HSCs and control HSCs. Arrows indicated the Casp3 immunoreactive cells. 475 
Scale bar: 100 μm. 476 
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